Abstract
Data remain limited regarding thrombosis among Thai patient with multiple myeloma patients and who experience thromboembolic events face a higher mortality rate compared to those without such complications The primary objective is to determine the prevalence of symptomatic venous and arterial thrombosis in Thai multiple myeloma patients, with secondary objectives including identifying survival impact of thrombosis and associated factors of thrombosis. The study includes newly diagnosed multiple myeloma patients from the single site of tertiary care center in Thailand between 2018 and 2022. Of the 146 enrolled patients, The prevalence of symptomatic venous thromboembolism, arterial thrombosis, and both thromboses were 8.22%, 1.37%, and 0.68% respectively. No difference of overall survival between thrombotic and non-thrombotic groups, the 3 years overall survival rates among multiple myeloma patients with and without thrombotic events were 0.6 [95%CI: 0.37-0.97] and 0.63 [95%CI: 0.54-0.73] respectively. In multivariable logistic regression analysis thromboprophylaxis seemed to be associated with lower risk of thrombotic events in our patient population [OR: 0.05] without increase risk of bleeding. The prevalence of symptomatic venous thromboembolism and arterial thrombosis among Thai multiple myeloma patients was relatively low. Thromboprophylaxis is protective factor for thrombosis without increased risk of bleeding. There is no survival impact of thrombosis in multiple myeloma patient.